Eisai Looking to Enhance Treatment with Monthly Dose of Leqembi

Monday, 1 April 2024, 10:04

Eisai has submitted a supplemental biologics license application (sBLA) to the FDA seeking approval for a monthly maintenance dose of their Alzheimer's drug Leqembi. This move aims to provide improved treatment options for patients with Alzheimer's disease, potentially enhancing the efficacy of the therapy in managing the condition.

https://store.livarava.com/7e71287b-f00f-11ee-8919-87cc5c87fb08.jpg — Eisai Looking to Enhance Treatment with Monthly Dose of Leqembi

Eisai Submits sBLA for Monthly Maintenance Dose of Alzheimer's Drug Leqembi

Eisai has submitted a supplemental biologics license application (sBLA) to the FDA for a monthly maintenance dose of Alzheimer's therapy Leqembi.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.